AbbVie Inc (ABBV)vsBrookdale Senior Living Inc (BKD)
ABBV
AbbVie Inc
$246.04
+0.89%
HEALTHCARE · Cap: $430.82B
BKD
Brookdale Senior Living Inc
$14.22
-0.97%
HEALTHCARE · Cap: $3.49B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2045% more annual revenue ($64.39B vs $3.00B). ABBV leads profitability with a 9.8% profit margin vs -6.8%. BKD appears more attractively valued with a PEG of 0.28. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
BKD
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-63.1%
Fair Value
$150.90
Current Price
$246.04
$95.14 premium
Margin of Safety
+62.2%
Fair Value
$38.65
Current Price
$14.22
$24.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 39.6%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Weak financial health signals
ROE of -437.5% — below average capital efficiency
Revenue declined 6.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : BKD
The strongest argument for BKD centers on PEG Ratio, Debt/Equity. PEG of 0.28 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 68.9x leaves little room for execution misses.
Bear Case : BKD
The primary concerns for BKD are EPS Growth, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while BKD is a turnaround play — different risk/reward profiles.
BKD carries more volatility with a beta of 0.58 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 39/100) and 10.2% revenue growth. BKD offers better value entry with a 62.2% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Brookdale Senior Living Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Brookdale Senior Living Inc. owns and operates senior communities in the United States. The company is headquartered in Brentwood, Tennessee.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?